COVID-19 Resource Center

COVID-19 Resource Center

Source:

Press Release.

Disclosures: Healio could not confirm relevant financial disclosures for Cohen at the time of publication.
April 12, 2021
2 min read
Save

Subcutaneous injection of antibody cocktail reduces risk for symptomatic SARS-CoV-2

Source:

Press Release.

Disclosures: Healio could not confirm relevant financial disclosures for Cohen at the time of publication.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

One subcutaneous injection of REGEN-COV — a combination of two monoclonal antibodies — reduced the risk for symptomatic SARS-CoV-2 infection by more than 80% among household contacts of infected individuals, Regeneron said.

The finding, announced in a press release, was from a phase 3 trial run by Regeneron and the National Institute of Allergy and Infectious Diseases. The cocktail includes the monoclonal antibodies casirivimab with imdevimab.

COVID data
A phase 3 trial demonstrated that REGEN-COV reduced the risk for COVID-19 infection among household contacts of infected individuals by more than 80%.
Source: Adobe Stock

“These data suggest that REGEN-COV can complement widespread vaccination strategies, particularly for those at high risk of infection. Importantly, to date REGEN-COV has been shown in vitro to retain its potency against emerging COVID-19 variants of concern," Myron S. Cohen, MD, who heads monoclonal antibody efforts for the NIH-sponsored COVID Prevention Network and is director of the Institute for Global Health & Infectious Diseases at the University of North Carolina at Chapel Hill, said in the release.

According to the release, the phase 3, double-blind, placebo-controlled trial assessed the effect of REGEN-COV on uninfected individuals without anti-SARS-CoV-2 antibodies or any COVID-19 symptoms who lived in the same household as an individual who tested positive for SARS-CoV-2 within the prior 4 days. In total, the researchers randomly assigned 1,505 people who were not infected with SARS-CoV-2 to receive either one 1,200 mg dose of REGEN-COV or placebo, given subcutaneously.

The study demonstrated that REGEN-COV “rapidly protected” household contacts from exposure, with 72% protection against symptomatic infections in the first week and 93% in subsequent weeks. The protection was 81% through 29 days, the primary endpoint Additionally, the study showed that individuals treated with REGEN-COV who experienced a symptomatic infection experienced resolved symptoms in just 1 week compared with 3 weeks with placebo, and they cleared the virus faster, according to the release.

Adverse events (AEs) in the study occurred in 20% (n = 265 out of 1,311) of participants in the treatment arm and 29% (n = 379 out of 1,306) of participants in the placebo arm, with serious AEs occurring in 1% (n = 10) of REGEN-COV and 1% (n = 15) of placebo participants.

The FDA has authorized the emergency use of casirivimab and imdevimab for use in patients aged 12 years or older with a positive SARS-CoV-2 test who are at risk for progression to severe COVID-19. Regeneron said it will share the new data with the FDA and request an emergency use expansion to include COVID-19 prevention for appropriate populations, according to the press release.

“If authorized, convenient subcutaneous administration of REGEN-COV could help control outbreaks in high-risk settings where individuals have not yet been vaccinated, including individual households and group living settings," Cohen said.